Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Xu RH, et al. Among authors: matsuoka h. Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. Lancet Oncol. 2018. PMID: 29555258 Clinical Trial.
Prognosis in gastric cancer associated with pregnancy.
Ueo H, Matsuoka H, Tamura S, Sato K, Tsunematsu Y, Kato T. Ueo H, et al. Among authors: matsuoka h. World J Surg. 1991 Mar-Apr;15(2):293-7, discussion 298. doi: 10.1007/BF01659068. World J Surg. 1991. PMID: 2031366
[HAI chemotherapy for liver metastases of colorectal cancer].
Matsuoka H, Maeda K, Hanai T, Sato H, Masumori K, Koide Y, Katsuno H, Agata T, Noro T, Honda K, Shiota M, Ozeki S, Hatta K, Morise Z, Sugioka A, Ota H. Matsuoka H, et al. Gan To Kagaku Ryoho. 2010 Jul;37(7):1303-6. Gan To Kagaku Ryoho. 2010. PMID: 20647714 Japanese.
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Takahashi T, et al. Among authors: matsuoka h. Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2. Int J Clin Oncol. 2013. PMID: 22383023 Clinical Trial.
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Tezuka T, et al. Among authors: matsuoka h. Invest New Drugs. 2013 Oct;31(5):1321-9. doi: 10.1007/s10637-013-9982-3. Epub 2013 Jul 2. Invest New Drugs. 2013. PMID: 23817973 Free PMC article. Clinical Trial.
A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y, Hirata K, Matsuoka H, Iwamoto S, Kotaka M, Fujita H, Aisu N, Hoshino S, Kosaka T, Maeda K, Kiyomi F, Yamashita Y. Yoshida Y, et al. Among authors: matsuoka h. Drug Des Devel Ther. 2015 Nov 11;9:6067-73. doi: 10.2147/DDDT.S94901. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26648694 Free PMC article. Clinical Trial.
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: matsuoka h. Ann Surg Oncol. 2017 Feb;24(2):546-553. doi: 10.1245/s10434-016-5557-9. Epub 2016 Sep 8. Ann Surg Oncol. 2017. PMID: 27638675 Clinical Trial.
Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: matsuoka h. Ann Surg Oncol. 2016 Dec;23(Suppl 5):1064. doi: 10.1245/s10434-016-5593-5. Ann Surg Oncol. 2016. PMID: 27646021 No abstract available.
2,241 results